Extracellular Matrix-Inspired Growth Factor Delivery Systems for Skin Wound Healing

被引:170
作者
Briquez, Priscilla S. [1 ,2 ]
Hubbell, Jeffrey A. [1 ,2 ,3 ,4 ]
Martino, Mikael M. [5 ]
机构
[1] Ecole Polytech Fed Lausanne, Sch Life Sci, Inst Bioengn, Lausanne, Switzerland
[2] Ecole Polytech Fed Lausanne, Sch Engn, Lausanne, Switzerland
[3] Univ Chicago, Inst Mol Engn, Chicago, IL 60637 USA
[4] Argonne Natl Lab, Div Mat Sci, Argonne, IL 60439 USA
[5] Osaka Univ, World Premier Int Immunol Frontier Res Ctr, 3-1 Yamadaoka, Suita, Osaka 5650871, Japan
基金
欧洲研究理事会; 瑞士国家科学基金会;
关键词
FACTOR-BINDING; DRUG-DELIVERY; FIBRONECTIN; INTEGRIN; PATHOPHYSIOLOGY; ANGIOGENESIS; VITRONECTIN; DRESSINGS; PROMOTION; HYDROGEL;
D O I
10.1089/wound.2014.0603
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Significance: Growth factors are very promising molecules for the treatment of skin wounds. However, their translation to clinical use has been seriously limited, facing issues related to safety and cost-effectiveness. These problems may derive from the fact that growth factors are used at vastly supra-physiological levels without optimized delivery systems. Recent Advances: The extracellular matrix (ECM) plays a fundamental role in coordinating growth factor signaling. Therefore, understanding the mechanisms by which the ECM modulates growth factor activity is key for designing efficient growth factor-based therapies. Recently, several growth factor-binding domains have been discovered within various ECM proteins, and growth factor delivery systems integrating these ECM growth factor-binding domains showed promising results in animal models of skin wound healing. Moreover, a novel strategy consisting of engineering growth factors to target endogenous ECM could substantially enhance their efficacy, even when used at low doses. Critical Issues: Optimal delivery of growth factors often requires complex engineered biomaterial matrices, which can face regulatory issues for clinical translation. To simplify delivery systems and render strategies more applicable, growth factors can be engineered to optimally function with clinically approved biomaterials or with endogenous ECM present at the delivery site. Future Directions: Further development and clinical trials will reveal whether growth factor-based therapies can be used as main therapeutic approaches for skin wound healing. The future impact of these therapies will depend on our capacity to deliver growth factors more precisely, to improve efficacy, safety, and cost-effectiveness.
引用
收藏
页码:479 / 489
页数:11
相关论文
共 61 条
[1]  
Agren Magnus S, 2007, Int J Low Extrem Wounds, V6, P82, DOI 10.1177/1534734607301394
[2]  
[Anonymous], EPLASTY
[3]  
[Anonymous], EUR MUSCULOSKELET RE
[4]  
[Anonymous], IMPORTANCE GROWTH FA
[5]  
[Anonymous], BR J COMMUN NURS
[6]   Platelet-Rich Plasma: A Literature Review [J].
Arora, Navneet S. ;
Ramanayake, Thaminda ;
Ren, Yan-Fang ;
Romanos, Georgios E. .
IMPLANT DENTISTRY, 2009, 18 (04) :303-310
[7]   Growth factors and cytokines in wound healing [J].
Barrientos, Stephan ;
Stojadinovic, Olivera ;
Golinko, Michael S. ;
Brem, Harold ;
Tomic-Canic, Marjana .
WOUND REPAIR AND REGENERATION, 2008, 16 (05) :585-601
[8]   Growth factors in the treatment of diabetic foot ulcers [J].
Bennett, SP ;
Griffiths, GD ;
Schor, AM ;
Leese, GP ;
Schor, SL .
BRITISH JOURNAL OF SURGERY, 2003, 90 (02) :133-146
[9]   Accelerated diabetic wound healing using cultured dermal fibroblasts retrovirally transduced with the platelet-derived growth factor B gene [J].
Breitbart, AS ;
Laser, J ;
Parrett, B ;
Porti, D ;
Grant, RT ;
Grande, DA ;
Mason, JM .
ANNALS OF PLASTIC SURGERY, 2003, 51 (04) :409-414
[10]   Understanding chronic wound healing [J].
Broderick, Nancy .
NURSE PRACTITIONER, 2009, 34 (10) :16-22